Skip to main
RANI
RANI logo

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 73%
Buy 27%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Holdings Inc. is poised for significant growth due to its proprietary RaniPill technology, which facilitates the oral delivery of biologics, potentially replacing painful injections and appealing to both patients and healthcare providers. The company has demonstrated impressive preclinical results in canines, indicating strong potential for positive outcomes in human trials, particularly with the upcoming Phase 1c trial targeting non-diabetic obesity. Additionally, Rani's collaborations and focus on the lucrative obesity market present substantial opportunities, further enhancing the attractiveness of its innovative biotherapeutic solutions.

Bears say

Rani Therapeutics Holdings Inc faces several significant challenges that could negatively impact its stock outlook, primarily due to intense competition and management instability. The presence of numerous companies pursuing long-acting injectable formulations may diminish the competitive edge of Rani's oral RaniPill technology, while ongoing management turnover poses risks of disruption to clinical development and delayed progress. Additionally, the company's pipeline includes programs with uncertain FDA approval prospects and potential market resistance, further complicating its ability to achieve meaningful market penetration and financial success.

RANI has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 73% of analysts recommend a Strong Buy, 27% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 11 analysts, RANI has a Strong Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.